Gut Microbiota and Cancer Immunotherapy
Dr. Andrew Y. Koh from the University of Texas Southwestern Medical Center, USA will join the Targeting Microbiota 2023 congress and will give a speech entitled "Gut Microbiota and Cancer Immunotherapy".
Gut microbiota, specifically gut bacteria, are critical for effective immune checkpoint blockade therapy (ICT) for cancer. The mechanisms by which gut microbiota augment extraintestinal anticancer immune responses, however, are largely unknown. Dr. Koh and his team find that ICT induces the translocation of specific endogenous gut bacteria into secondary lymphoid organs and subcutaneous melanoma tumors.
Mechanistically, ICT induces lymph node remodeling and dendritic cell (DC) activation, which facilitates the translocation of a selective subset of gut bacteria to extraintestinal tissues to promote optimal antitumor T cell responses in both the tumor-draining lymph nodes (TDLNs) and the primary tumor. Antibiotic treatment results in decreased gut microbiota translocation into mesenteric lymph nodes (MLNs) and TDLNs, diminished DC and effector CD8+ T cell responses, and attenuated responses to ICT.
Those findings illuminate a key mechanism by which gut microbiota promote extraintestinal anticancer immunity
Join us in Targeting Microbiota 2023 and benefit from the experience of Dr. Koh. Don't forget that you can share your related work by submitting your abstract.
Targeting Microbiota 2023 Congress
October 17-19, 2023 - Venice
Linkedin | Facebook | Website
